{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:57:30Z","timestamp":1787986650214,"version":"build-2784847793"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.euroneuro.2018.10.008","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T10:25:06Z","timestamp":1542709506000},"page":"127-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II\/III studies"],"prefix":"10.1016","volume":"29","author":[{"given":"Stephen","family":"Marder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Wolfgang","family":"Fleischhacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willie","family":"Earley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"N\u00e9meth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Laszlovszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erzs\u00e9bet","family":"Szalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Durgam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2018.10.008_bib0001","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2000"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0002","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4088\/JCP.15m10192","article-title":"The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials","volume":"77","author":"Citrome","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.schres.2011.05.018","article-title":"Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis","volume":"131","author":"Citrome","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0004","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1017\/S1092852914000054","article-title":"The psychopharmacology of violence: making sensible decisions","volume":"19","author":"Citrome","year":"2014","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0005","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4088\/JCP.v67n0415","article-title":"Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, open-label study data","volume":"67","author":"Citrome","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0006","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1176\/appi.ps.52.11.1510","article-title":"Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia","volume":"52","author":"Citrome","year":"2001","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0007","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.schres.2006.09.027","article-title":"The burden of depressive symptoms in the long-term treatment of patients with schizophrenia","volume":"90","author":"Conley","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0008","doi-asserted-by":"crossref","first-page":"B16","DOI":"10.1016\/j.clinthera.2011.11.016","article-title":"Quantifying clinical relevance in the treatment of schizophrenia","volume":"33","author":"Correll","year":"2011","journal-title":"Clin. Ther."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0009","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00004714-199508000-00002","article-title":"Effect of risperidone on hostility in schizophrenia","volume":"15","author":"Czobor","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0010","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4088\/JCP.v62n1003","article-title":"The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials","volume":"62","author":"Davis","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0011","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/schbul\/sbx039","article-title":"Attacking heterogeneity in schizophrenia by deriving clinical subgroups from widely available symptom data","volume":"44","author":"Dickinson","year":"2017","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0012","doi-asserted-by":"crossref","first-page":"e1574","DOI":"10.4088\/JCP.15m09997","article-title":"Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial","volume":"76","author":"Durgam","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0013","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial","volume":"152","author":"Durgam","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0014","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/ijnp\/pyx038","article-title":"Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model","volume":"20","author":"Duric","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0015","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [(11)C]-(+)-PHNO","volume":"233","author":"Girgis","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0016","series-title":"The Clinician Global Severity and Impression Scales","first-page":"218","author":"Guy","year":"1976"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0017","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00210-008-0311-x","article-title":"Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.","volume":"378","author":"Gyerty\u00e1n","year":"2008","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0018","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eurpsy.2011.02.015","article-title":"Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment","volume":"27","author":"Hunter","year":"2012","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0019","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4088\/JCP.08m04310","article-title":"The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies","volume":"70","author":"Janicak","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0020","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1359-6446(05)03491-4","article-title":"Dopamine D3 receptor antagonists as therapeutic agents","volume":"10","author":"Joyce","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0021","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial","volume":"35","author":"Kane","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0022","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0023","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"issue":"supplement 1","key":"10.1016\/j.euroneuro.2018.10.008_bib0024","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1016\/S0920-9964(12)70588-1","article-title":"Cariprazine, a D3\/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics","volume":"136","author":"Kiss","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0025","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0026","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00210-008-0308-5","article-title":"Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.","volume":"378","author":"Kiss","year":"2008","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0027","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/archpsyc.63.6.622","article-title":"Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Krakowski","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0028","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0920-9964(99)00129-2","article-title":"Stability of the five-factor structure of the positive and negative syndrome scale (PANSS)","volume":"42","author":"Lancon","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0029","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00213-004-2096-z","article-title":"Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats","volume":"179","author":"Laszy","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejphar.2013.07.022","article-title":"Dopamine D receptor as a new pharmacological target for the treatment of depression","volume":"719","author":"Leggio","year":"2013","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0031","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0032","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF02354306","article-title":"A new five factor model of schizophrenia","volume":"65","author":"Lindenmayer","year":"1994","journal-title":"Psychiatr. Q."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0033","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4088\/JCP.v65n0416","article-title":"Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia","volume":"65","author":"Lindenmayer","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0034","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eurpsy.2014.08.001","article-title":"Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies","volume":"30","author":"Loebel","year":"2015","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0035","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0036","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/appi.ajp.162.3.495","article-title":"Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up","volume":"162","author":"Milev","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0037","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/S204579601100062X","article-title":"Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment","volume":"20","author":"Nasrallah","year":"2011","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0038","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.euroneuro.2015.11.016","article-title":"Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology","volume":"26","author":"Neill","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0039","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","author":"Nemeth","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1755-5949.2010.00222.x","article-title":"Antipsychotic occupancy of dopamine receptors in schizophrenia","volume":"17","author":"Nord","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0041","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1176\/appi.ajp.161.1.53","article-title":"Social anxiety in outpatients with schizophrenia: a relevant cause of disability","volume":"161","author":"Pallanti","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0042","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/FBP.0000000000000070","article-title":"Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression","volume":"25","author":"Papp","year":"2014","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0043","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/acps.12262","article-title":"A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation","volume":"130","author":"Pratts","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0044","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.schres.2013.07.014","article-title":"Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis","volume":"150","author":"Rabinowitz","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0045","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.schres.2013.06.023","article-title":"Negative symptoms in schizophrenia\u2013the remarkable impact of inclusion definitions in clinical trials and their consequences","volume":"150","author":"Rabinowitz","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0046","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1034\/j.1600-0447.2003.00132.x","article-title":"Depression and subjective quality of life in chronic phase schizophrenic patients","volume":"108","author":"Reine","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0047","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0165-0173(99)00043-0","article-title":"Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions","volume":"31","author":"Schwartz","year":"2000","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0048","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2147\/NDT.S81024","article-title":"Predictors of quality of life among individuals with schizophrenia","volume":"11","author":"Suttajit","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0049","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1017\/S1092852914000364","article-title":"Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the clinical antipsychotic trials of intervention effectiveness (CATIE) study - addendum","volume":"19","author":"Volavka","year":"2014","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0050","doi-asserted-by":"crossref","first-page":"955","DOI":"10.4088\/JCP.10m06529","article-title":"Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST)","volume":"72","author":"Volavka","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0051","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2012.01.031","article-title":"Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia","volume":"137","author":"Wallwork","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0052","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.euroneuro.2015.12.020","article-title":"The dopamine D(3)-preferring D(2)\/D(3) dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia","volume":"26","author":"Watson","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.10.008_bib0053","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00213-012-2896-5","article-title":"Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse","volume":"226","author":"Zimnisky","year":"2013","journal-title":"Psychopharmacology"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18308435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18308435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:51:46Z","timestamp":1760377906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X18308435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0924977X18308435"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.10.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II\/III studies","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}